Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Prostate Cancer > Studies > Flashcards

Studies Flashcards

1
Q

What are the major RT dose escalation trials?

A

MRC RT01
Dutch CKVO96-10
PROG 9509
MD Anderson (Kuban)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the trials that examine short term ADT + RT vs. RT alone?

A 
TROG 96.01
D'Amico 
RTOG 9408
Quebec L-101
RTOG 8610
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the trials that examine long term ADT + RT vs. RT alone?

A

RTOG 8531
EORTC 22863
Quebec L-101
Casodex EPC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Arms for TROG 9601?

A

RCT comparing 3 VS 6 MO ADT VS RT ALONE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are the trials that examine neoadjuvant ADT vs. adjuvant?

A

RTOG 9413

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Arms for RTOG 8531?

A

RT Alone vs. RT + ADT until progression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Arms for CASODEX EPC trial?

A

RT Alone vs. RT + antiandrogen until progression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What trials evaluated duration of ADT with RT?

A 
RTOG 9202
Quebec L-200
Canadian trial 
TROG 96.01
EORTC 22961
ICORG 97.01
PCS IV
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

SPCG-7 CATEGORY

A

RCT LONG TERM ADT WITH FLUTAMIDE +/- EBRT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Studies evaluating pelvic nodal RT vs. no pelvic nodal RT?

A

RTOG 7706
GETUG 01
RTOG 9413

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Current RCTs examining adjuvant and salvage RT?

A

RADICALs
GETUG-1
RAVES

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

RCT examining adjuvant RT +/- casodex?

A

RTOG 9601

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

EUROPEAN STUDY RCT EXAMINING ADJUVANT RT VS. OBS

A

EORTC 22911

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

GERMAN RECT EXAMINING ADJUVANT RT VS. OBS?

A

GERMAN ARO 96-02

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

RCT examining 3 vs 10 mo ADT +RT vs. RT alone?

A

Quebec L-101

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

University of Calgary RCT major results?

A

Cryotherapy vs. RT

7 year bF 27% vs. 32%, NS
5 year OS 90% vs. 88%, NS

17
Q

University of Calgary RCT toxicity results?

A

Cryotherapy vs. RT

G3-4 GU 9% vs. 6%, NS
G3-4 GI 3% vs. 7%, NS

Sexual potency 4% vs. 26%, SS

18
Q

University of Calgary inclusion criteria?

A

cT2-3 N0
PSA < 20
Prostate volume < 60 cc
***PLND if GS 8+

19
Q

EORTC 22911 inclusion criteria

A

75 yo or less
pT3a or b or positive margin
Undectable PSA was not required

20
Q

In EORTC 22911 what percentage of patients had a PSA > 0.2?

A

29.9%

21
Q

EORTC 22911 arms?

A

Adjuvant radiation vs. observation

22
Q

EORTC 22911 10 year locoregional relapse rate?

A

OBS vs. ADJ RT

16% vs. 7.3%, SS

23
Q

EORTC 22911 major 10 year findings?

A

OBS vs. ADJ RT

bPFS 41% vs. 61%, SS
OS 80% vs. 76%, NS

24
Q

EORTC 22911 RT details

A

PORT 60 Gy at 2 Gy/fx
Cone down at 50 Gy was done
No pelvic nodal RT

25
Q

EORTC 22911 PEP

A

Biochemical failure defined as PSA > 0.2 measured on two separate occurrences

26
Q

EORTC 22911 10 year toxicity

A

OBS vs. ADJ RT

G3 GU 2.5% vs. 5.3%, SS
G2-3 GI 2.5% vs. 1.9%, NS

27
Q

ARO 9602 inclusion criteria

A

After RP for PC:
pT3-4 with +/- margins
Undetectable PSA after RP
75 years or less

28
Q

RTOG 9202 inclusion criteria?

A
  1. T2c-T4

2. PSA < 150

29
Q

RTOG 9202 arms?

A
  1. RT to 65-70 Gy + CADT for 4 months for flutimide and goserelin
  2. RT + CADT for 4 months and for an additional 2 years with goserelin alone
30
Q

RTOG 9202 subgroup results for patients with GS 8-10 disease?

A

LT ADT improved with SS

  1. DFS (9% vs. 21%), SS
  2. DSS (66% vs. 80%), SS
  3. Local progression (27% vs. 17%), SS
  4. DM 40% vs. 25%, SS
  5. Biochemical failure 73% vs. 55%, SS
  6. OS 31% vs, 45%, SS
31
Q

According to Brenner et al using data from SEER what is the risk of prostate radiation causing secondary cancers?

A

1/70 at 10 years, 1.4%

32
Q

What was the purpose of Lawton’s 2005 RJ publication focusing on node positive patients from RTOG 8531?

A

RT vs. RT + immediate ADT and its impact on OS, bPFS, DM and local control

33
Q

In Lawton’s 2005 RJ publication focusing on node positive patients from RTOG 8531, in patients treated with RT alone vs. RT + ADT what was 10 year OS? biochemical control? FFDM?

A

RT + ADT vs. RT Alone
bPFS: 35% vs. 5%, SS
FFDM: 67% vs. 52%, SS
OS: 47% vs. 31%, NS

34
Q

In Lee et al 1994, Urology publication following 71 patients with pathologically positive nodes treated with RT alone, what was the 10 year OS, LC, and DM?

A 
10 year 
LC: 45% 
DM: 82%
RFS: 10% 
CSS: 25%
OS: 20%
35
Q

Which study compared early vs. delayed ADT alone for clinically node positive patients?

A

EORTC 30846

36
Q

What was the median OS for patients receiving immediate ADT for clinically node positive prostate cancer in EORTC 30846?

A

7.6 years

37
Q

What was the 10 year PCSM for patients receiving immediate ADT for clinically node positive prostate cancer in EORTC 30846?

A

57% at 10 years

39
Q

What trials examined the question of long term ADT + RT. vs RT alone?

A

Casodex
EORTC 22961
RTOG 8531
EORTC 22863

Prostate Cancer (2 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions